



(FW)

Attorney Docket: 27098U

Date: April 13, 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Art Unit: 1614

VENNEMANN, et al.

Examiner: Unknown

Appl. No.: 10/562,137 /

Filed: December 23, 2005

For: **PYRROLODIHYDROISOQUINOLINES AS PDE10 INHIBITORS**

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:

- 1) Information Disclosure Statement;
- 2) PTO Form-1449 with 29 cited References, with copies for 25 of the 29 cited References.

The Commissioner is hereby authorized to charge any deficiency or credit any excess to Deposit Account No. 14-0112.

Respectfully submitted,
NATH & ASSOCIATES PLLC



Gary M. Nath, Reg. No. 26,965
Sheldon M. McGee, Reg. No. 50,454
Customer No. 34375

NATH & ASSOCIATES PLLC
112 South West Street
Alexandria, VA 22314

GMN/SMM/le



Attorney Docket: 27098U

Date: April 13, 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Art Unit: 1614

VENNEMANN, et al.

Examiner: Unknown

Appl. No.: 10/562,137

Filed: December 23, 2005

For: **PYRROLODIHYDROISOQUINOLINES AS PDE10 INHIBITORS**

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. 1.97-1.98. Please note the following particulars: [NOTE: One only of items a, b, c, and d must be checked.]

- [XXX] a. The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.
- [] b. The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311.
The enclosed statement is accompanied by [check one]:
[] i. a certification in part (e) below as specified in 37 C.F.R. 1.97(e), or
[] ii. a check in the amount required by 37 C.F.R. 1.17(p).
- [] c. The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311, but before payment of the issue fee.

☐ Certification report(e) below; and
☐ a check in the amount as required by 1.17(p).

☐ d. The enclosed statement is being filed pursuant to 37 C.F.R. 1.97(i), for placement in the file.

☐ e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]

☐ I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,
or

☐ I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

or

☐ Appropriate certification is attached.

[XXX] f. If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.

[XXX] g. Copies of the documents are attached herewith with a completed Form PTO-1449.

or

[] Copies of the documents are not attached as allowed under CFR 1.98(d)(1)(2). The earlier application is identified as:


and / or

[XXX] Copies of US Patents/Publications not attached as allowed in Official Gazette Aug. 5, 2003/ Vol. 1273, no. 1.

The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted,
NATH & ASSOCIATES PLLC


Gary M. Nath, Reg. No. 26,965
Sheldon M. McGee, Reg. No. 50,454
Customer No. 34375

NATH & ASSOCIATES PLLC
112 South West Street
Alexandria, VA 22314

GMN/SMM/le

APR 13 2006

Attorney Docket: 27098U

FORM PTO-1449

In re Application of:
VENNEMANN, et al.Art Unit:
1614Appl. No:
10/562,137Filed:
December 23, 2005Examiner:
Unknown**INFORMATION DISCLOSURE CITATION****U.S. PATENT DOCUMENTS**

Examiner Initial		Document Number	Issue / Publication Date	Inventor	Filed
/R.D./	A1	5,965,575	12 Oct. 1999	Peglion et al.	27 Mar. 1998
/R.D./	A2	2003/0008806	9 Jan. 2003	Lebel et al.	19 Apr. 2002
/R.D./	A3	2003/0018047	23 Jan. 2003	Lebel et al.	3 May 2002
/R.D./	A4	2003/0032579	13 Feb. 2003	Lebel et al.	20 Jun. 2002

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document Number	Publication Date	Country	Translation
/R.D./	A5	1 250 923 A2	23 Oct. 2002	EP	N/A
/R.D./	A6	98/55118 A2	10 Dec. 1998	WO	N/A
/R.D./	A7	01/24781 A2	12 Apr. 2001	WO	N/A
/R.D./	A8	02/48144 A1	20 Jun. 2002	WO	N/A
/R.D./	A9	03/000269 A2	3 Jan. 2003	WO	Abstract

OTHER

Examiner Initial		(Including Author, Title, Date, Pertinent Pages, etc.)
/R.D./	A10	Benovsky, P., et al., "Aza-Annulation as a Versatile Approach to the Synthesis of Non-Benzodiazepene Compounds for the Treatment of Sleep Disorders", <u>Tetrahedron Letters</u> , vol. 38, no. 49, pp. 8475-8478, (1997).
/R.D./	A11	Díaz, M., et al., "Syntheses of Lamellarins I and K by [3+2] Cycloaddition of a Nitron to an Alkyne", <u>Synlett</u> , no. 7, pp. 1164-1166, (2001).
/R.D./	A12	Fujishige, K., et al., "Cloning and Characterization of a Novel Human Phosphodiesterase that Hydrolyzes Both cAMP and cGMP (PDE10A)", <u>The Journal of Biological Chemistry</u> , vol. 274, no. 26, pp. 18438-18445, (1999).
/R.D./	A13	Fujishige, K., et al., "The human phosphodiesterase PDE10A gene", <u>Eur. J. Biochem.</u> , vol. 267, pp. 5943-5951, (2000).
/R.D./	A14	Fujishige, K., et al., "Striatum- and testis-specific phosphodiesterase PDE10A: Isolation and characterization of a rat PDE10A", <u>Eur. J. Biochem.</u> , vol. 266, pp. 1118-1127, (1999).
/R.D./	A15	Govindachari, T.R., et al., "Application of the Bruckner Method to the Synthesis of Phenanthridine Derivatives", <u>J. Chem. Soc.</u> , pp. 4280-4283, (1956).

Examiner

/Rita Desai/

Date Considered

05/20/2009

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP ' 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE CITATION	In re Application of: VENNEMANN, et al.		Art Unit: 1614
	Appl. No: 10/562,137	Filed: December 23, 2005	Appl. No: 10/562,137

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Issue / Publication Date	Inventor	Filed
A16				

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document Number	Publication Date	Country	Translation
/R.D./	A17	03/014115 A1	20 Feb. 2003	WO	N/A
	A18	03/014116 A1	20 Feb. 2003	WO	N/A
	A19	03/014117 A1	20 Feb. 2003	WO	N/A
	A20	03/051877 A1	26 Jun. 2003	WO	N/A
	A21	03/077949 A2	25 Sep. 2003	WO	N/A
	A22	03/093499 A2	13 Nov. 2003	WO	N/A
	A23	2005/002579 A1	13 Jan. 2005	WO	N/A
/R.D./	A24	2005/003130 A1	13 Jan. 2005	WO	N/A

OTHER

Examiner Initial	(Including Author, Title, Date, Pertinent Pages, etc.)
/R.D./	A25 Hershenson, F.M., "Synthesis of Ring-Fused Pyrroles. II. 1,3-Dipolar Cycloaddition Reactions of Munchnone Derivatives Obtained from Tetrahydroisoquinoline-1-carboxylic Acids", <u>J. Org. Chem.</u> , vol. 40, no. 6, (1975).
/R.D./	A26 Kotera, J., et al., "Characterization and Phosphorylation of PDE10A2, a Novel Alternative Splice Variant of Human Phosphodiesterase that Hydrolyzes cAMP and cGMP", <u>Biochemical and Biophysical Research Communications</u> , vol. 261, pp. 551-557, (1999).
/R.D./	A27 Loughney, K., et al., "Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3',5'-cyclic nucleotide phosphodiesterase", <u>Gene</u> , vol. 216, pp. 139-147, (1998).
/R.D./	A28 Meyer, H., "Pyrrole durch cyclisierende Michael-Addition von Enaminen", <u>Liebigs Ann. Chem.</u> , pp. 1534-1544, (1981). (ABSTRACT)
/R.D./	A29 Shepard, E.R., et al., "Preparation of Some Analogs of Papaverine", <u>J. Org. Chem.</u> , vol. 17, pp. 568-576, (1952).
/R.D./	A30 Soderling, S.H., et al., "Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A", <u>Proc. Natl. Acad. Sci. USA</u> , vol. 96, pp. 7071-7076, (1999).

Examiner /Rita Desai/	Date Considered 05/20/2009
--------------------------	-------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP ' 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.